← Analyst Upside
AU · rank #1 · 2026-07-24
DIA
GPW · PLN · $1.47B (USD)
SignalStrong Buy10.0strength 10.0 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.299 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.38 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $204.28 | +23.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +13.59% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.33 |
| Gross margin TTM | +79.3% |
| 52w high | $214.46 |
| Market cap (USD) | $1.47B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Diagnostyka S.A. is Poland's leading medical diagnostics network operator, running over 150 laboratories and 1,100 collection points serving institutional and individual clients.
Rationale
The 23% analyst upside signal is validated by robust Q1 2026 mid-teens revenue and profit growth, high pricing power, and an ROE exceeding 40%.
Material risks
- 1Long-term technological displacement of the centralized laboratory model as point-of-care and home testing commoditize routine diagnostic services.
- 2Institutional customers, such as universities and medical facilities, insourcing diagnostic capabilities and ending high-volume contracts.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed